Enzychem Lifesciences said on Friday that its COVID-19 treatment candidate EC-18 was granted by the FDA to carry out Phase II trial on confirmed patients, as reported The Korea Herald.
In the trial, the company will confirm the therapeutic effects of EC-18 for acute respiratory distress syndrome prevalent in COVID-19 patients with pneumonia.
The study will include 60 COVID-19 patients, of whom 30 will be given the standard treatment with EC-18, while the rest will be given standard treatment with placebo.
Korean drug authorities have also given the approval for the drug to proceed to a Phase II trial.
To read more NewsPoints articles, click here.